Clinical Trial Update: NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of neoadjuvant trastuzumab plus BKM120 with weekly paclitaxel in HER2-positive primary breast cancer completed; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• BKM120 (Buparlisib)
• PACLITAXEL (PACLITAXEL)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: HER2-positive Newly Diagnosed, Primary Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2019-11-14